Management of multiple sclerosis - PubMed (original) (raw)

Review

Management of multiple sclerosis

R A Rudick et al. N Engl J Med. 1997.

No abstract available

PubMed Disclaimer

Similar articles

• Current disease-modifying therapies in multiple sclerosis.
  Kieseier BC, Hartung HP. Kieseier BC, et al. Semin Neurol. 2003 Jun;23(2):133-46. doi: 10.1055/s-2003-41138. Semin Neurol. 2003. PMID: 12894379 Review.
• [Review of the therapy of multiple sclerosis].
  De Rosa A, Puccini A, De Martino V. De Rosa A, et al. Recenti Prog Med. 1982 Dec;73(6):651-68. Recenti Prog Med. 1982. PMID: 6308734 Review. Italian. No abstract available.
• [Diagnostics and drug therapy of multiple sclerosis].
  Suomen Neurologinen Yhdistys ry. Suomen Neurologinen Yhdistys ry. Duodecim. 2002;118(13):1411-23. Duodecim. 2002. PMID: 12239889 Finnish. No abstract available.
• Glatiramer: a second look. With longer follow-up: still no proven benefit in multiple sclerosis.
  [No authors listed] [No authors listed] Prescrire Int. 2009 Dec;18(104):252. Prescrire Int. 2009. PMID: 20025092 No abstract available.
• [Clinical surveillance of patients with multiple sclerosis].
  Cazzato G, Zorzon M. Cazzato G, et al. Recenti Prog Med. 2003 Apr;94(4):173-6. Recenti Prog Med. 2003. PMID: 12677789 Review. Italian.

Cited by

• Clinical management of contrast-induced neurotoxicity: a systematic review.
  Mariajoseph FP, Chung JX, Lai LT, Moore J, Goldschlager T, Chandra RV, Praeger A, Slater LA. Mariajoseph FP, et al. Acta Neurol Belg. 2024 Aug;124(4):1141-1149. doi: 10.1007/s13760-024-02474-4. Epub 2024 Feb 8. Acta Neurol Belg. 2024. PMID: 38329641 Free PMC article. Review.
• Potential of Nano-Engineered Stem Cells in the Treatment of Multiple Sclerosis: A Comprehensive Review.
  Ghosh S, Bhatti GK, Sharma PK, Kandimalla R, Mastana SS, Bhatti JS. Ghosh S, et al. Cell Mol Neurobiol. 2023 Dec 17;44(1):6. doi: 10.1007/s10571-023-01434-5. Cell Mol Neurobiol. 2023. PMID: 38104307 Review.
• Major depression favors the expansion of Th17-like cells and decrease the proportion of CD39+Treg cell subsets in response to myelin antigen in multiple sclerosis patients.
  do Sacramento PM, Sales M, Kasahara TM, Monteiro C, Oyamada H, Dias ASO, Lopes L, Castro CT, Rossi ÁD, Milioni LM, Agrawal A, Alvarenga R, Vasconcelos CC, Bento CAM. do Sacramento PM, et al. Cell Mol Life Sci. 2022 May 18;79(6):298. doi: 10.1007/s00018-022-04315-0. Cell Mol Life Sci. 2022. PMID: 35585332 Free PMC article.
• An Entropy Approach to Multiple Sclerosis Identification.
  Alfonso Perez G, Caballero Villarraso J. Alfonso Perez G, et al. J Pers Med. 2022 Mar 4;12(3):398. doi: 10.3390/jpm12030398. J Pers Med. 2022. PMID: 35330398 Free PMC article.
• Localized hydrogel delivery of dendritic cells for attenuation of multiple sclerosis in a murine model.
  Thomas AM, Beskid NM, Blanchfield JL, Rosado AM, García AJ, Evavold BD, Babensee JE. Thomas AM, et al. J Biomed Mater Res A. 2021 Jul;109(7):1247-1255. doi: 10.1002/jbm.a.37118. Epub 2020 Oct 16. J Biomed Mater Res A. 2021. PMID: 33040412 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information